782
Views
5
CrossRef citations to date
0
Altmetric
Review

An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease

, , &
Pages 11-16 | Published online: 20 Jan 2010

Abstract

Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low incidence of drug interactions. It has also been shown to be safe and effective in special patient populations, such as the elderly and those with renal or moderate liver disease.

Introduction to gastroesophageal reflux disease

In 2006, the Montreal Consensus Group provided a global evidence-based definition of gastroesophageal reflux disease (GERD) as “a condition which develops when the reflux of stomach contents [into the esophagus] causes troublesome symptoms and/or complications”.Citation1 It is a chronic, often relapsing disease that if not treated appropriately can lead to further complications including esophageal ulcers, stricture formation, obstruction, Barrett’s, and esophageal cancer. In addition, GERD can potentially lead to extra-esophageal complications, such as worsening asthma-like symptoms and chest pain.Citation2 Reports indicate that GERD affects an estimated 19 million people in the US alone. This figure is likely to be an under-representation as many patients are misdiagnosed and subsequently not appropriately treated.Citation3 Patients with GERD report a worse quality of life than those with diabetes, hypertension, mild heart failure, and angina.Citation4Citation6

Based on the 2005 practice guidelines, the mainstay of therapy for GERD is acid suppression.Citation7 Over the last 30 years, there has been an influx of various agents aimed at adequately controlling acid secretion and subsequently the symptoms of GERD. Since the discovery of the proton pump in the early 1970s and the subsequent development of proton pump inhibitors (PPIs); the mechanism by which GERD is treated has been revolutionized.Citation8 In 1989, omeprazole entered the market as the first PPI to treat acid reflux.Citation9 Then in 2000, pantoprazole became the fourth PPI marketed in the US and the first PPI to be available in both oral and intravenous (iv) forms.Citation10

Introduction of pantoprazole and its indications

After 8 years of research, Wyeth Pharmaceuticals introduced pantoprazole in April, 1985.Citation8 By 1994, pantoprazole was already in use throughout Europe but Food and Drug Administration (FDA) approval for use in the US did not occur until 2000Citation8 (). Initially, pantoprazole was approved for treatment and maintenance of erosive esophagitis (40 mg/day for 8 to 16 weeks).Citation9 Later in 2001, pantoprazole iv was approved for short-term treatment (7 to 10 days) of GERD patients and a history of erosive esophagitis (40 mg/day) who are unable to tolerate oral pantoprazole.Citation11 Since then, the indications for pantoprazole have expanded to include a variety of gastric acid-related diseases, including peptic ulcer disease (PUD), NSAID-induced ulcer prevention, Zollinger–Ellison syndrome, and adjunctive therapy for Helicobacter pylori eradication.Citation9

Table 1 FDA-approved indications for pantoprazole in the treatment of gastroesophageal reflux disease (GERD) in the US

Structure and physiology of pantoprazole

Pantoprazole is a membrane permeable substituted benzimidazole derivative that decreases gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase located within gastric parietal cells.Citation10,Citation12,Citation13 It has high tissue selectivity for the canalicular lumen of the parietal cell, which has a pH of 1.Citation14 Like other PPIs, it is a weakly basic prodrug that accumulates within this highly acidic environment and becomes rapidly activated into a cationic sulfonamide.Citation10,Citation13,Citation15 The protonated form then covalently binds to specific cysteine residues on the H+/K+ ATPase enzyme, thus irreversibly inactivating the pump. Compared to other PPIs, pantoprazole is less likely to become activated in neutral to moderately acidic environment s (pH 3 to 5). The narrow pH window prevents pantoprazole from acting at nontarget areas in the body, thus reducing adverse effects.Citation10,Citation14,Citation16 In vitro studies have shown that pantoprazole may actually have a longer duration of action than other PPIs because it is the only PPI to bind both cysteine 813 and cysteine 882, the more distal residue of the proton pump.Citation14 Theoretically, the distal site is less accessible to agents such as glutathione or dithiothreitol that potentially reverse proton pump inhibition.Citation17

Pharmacokinetics of pantoprazole

Pantoprazole follows dose linear pharmacokinetics. Oral pantoprazole has a bioavailability of 77% and its absorption is not affected by food or antacids.Citation10 It is ultimately absorbed in the small bowel, resulting in a maximum serum concentration 2 to 3 hours postingestion.Citation18 Therefore, pantoprazole is most effective when given prior to meals so it reaches peak serum levels when the maximum number of proton pumps are activated postprandially.Citation11 Unlike other PPIs, the serum concentration of pantoprazole is not dose-dependent; serum concentration after 1 dose is similar to that after multiple doses.Citation19 Pantoprazole is completely metabolized via the hepatic cytochrome P450 system by CYP2C19 and CYP3A4, and up to 80% of the inactive metabolites are eliminated via renal exctretion.Citation11,Citation12 The metabolism of pantoprazole is independent of the route of administration, with a half-life of approximately 1.1 hours.Citation10 However in patients with a mutation in the gene encoding the CYP2C19 enzyme, the half-life may be up to 3 hours.Citation20

Efficacy and current findings of pantoprazole

Numerous multicenter randomized control studies have shown pantoprazole to be more efficacious than histamine-2 receptor antagonists (H2RAs) as the first-line drug for both treatment and maintenance therapy of erosive esophagitis associated with GERD.Citation10,Citation21Citation24 Pantoprazole 40 mg/day for 4 to 8 weeks is the optimal regimen for the treatment of moderate to severe GERD.Citation25 Patients taking oral pantoprazole 40 mg/day had higher endoscopically confirmed healing rates at 4 weeks and 8 weeks, respectively, when compared with patients taking ranitidine 150 mg twice daily (54.0% to 95.1% vs 20.0% to 66.7% and 75.0% to 98.8% vs 41.0% to 77.4%, P < 0.001) or nitzatadine (79% vs 44%, P < 0.001).Citation10,Citation19,Citation22,Citation26,Citation27 Similarly, patients taking pantoprazole 40 mg/day had higher endoscopic remission rates than rantidine 150 mg twice daily (78.0% to 82% vs 21.0% to 33%, P < 0.001) for maintenance therapy at 12 months.Citation14,Citation28

When compared to other PPIs, pantoprazole has similarly efficacy in both the initial treatment and maintenance therapy of GERD. A double-blind, randomized, control study showed that pantoprazole 40 mg/day and esomeprazole 40 mg/day produce equivalent intraesophageal pH profiles and both similarly decrease esophageal acidity to normal levels 6 to 24 hours postingestion.Citation29 Endoscopic healing rates at 4 weeks and 8 weeks show no statistically significant differences when comparing pantoprazole 40 mg/day to omeprazole 20 mg/day, omeprazole multiple unit pellet system 40 mg/day, and lansoprazole 30 mg/day.Citation30Citation32 For maintenance therapy, pantoprazole 20 mg/day is equivalent to esomeprazole 20 mg/day for both endoscopic healing rates and symptom control at both 6 months and 12 months.Citation33,Citation34

Pantoprazole has been shown to improve health-related quality of life more effectively than H2RAs and with similar efficacy to other PPIs.Citation2,Citation5,Citation6,Citation35 Patients taking pantoprazole 40 mg/day had a greater percentage of symptom-free days at 12 months compared to patients taking ranitidine 150 mg twice daily (83% vs 58%, P < 0.001).Citation14 A similar study found pantoprazole to provide greater symptom relief than famotidine.Citation23 Although the efficacy seems to be relatively similar when comparing pantoprazole to other PPIs, limited data indicate that pantoprazole has a faster onset of symptom relief in patients with mild GERD.Citation36,Citation37 Similarly, in a study comparing pantoprazole 40 mg/day to esomeprazole 40 mg/day, patients treated with pantoprazole experienced less symptom relapse (51% vs 61%, P < 0.05) and fewer symptomatic episodes (56% vs 71%, P < 0.01) at one week post treatment than the esomeprazole group.Citation38 Pantoprazole 40 mg/day has also been shown to provide more effective control of night-time symptoms of GERD compared to esomeprazole 40 mg/day.Citation39 In the above studies, symptoms evaluated include heartburn, odynophagia, dysphagia, and acid regurgitation. Pantoprazole has positive patient satisfaction rates in trials involving patient questionnaires aimed at evaluating health-related quality of life such as ReQuest, GERDyzer, and the GERD symptom frequency questionnaire (GSFQ).Citation35,Citation40,Citation41

Since pantoprazole is effective in controlling symptoms related to GERD and improving health-related quality of life, interest has arisen in using pantoprazole on an as-needed basis, rather than every-day doses. This concept is known as on-demand therapy. Although not currently FDA approved, on-demand therapy with pantoprazole has been shown to be effective in the treatment of patients with mild GERD in randomized control studies.Citation42Citation44 In one study, patients with GERD were initially treated for 4 weeks with pantoprazole 20 mg/day, and subsequently received pantoprazole 20 mg/day or 40 mg/day for the following 6 months as needed for recurrent symptoms. A score was then calculated based on the patient’s perceived average daily symptom load. At 6 months, the mean symptom load scores were significantly lower in the treatment groups than in the placebo group (pantoprazole 20 mg: 2.91; pantoprazole 40 mg: 2.71; placebo: 3.93) (P < 0.0001).Citation44 There was no statistical difference between the two dosage groups of pantoprazole. Similarly, a study (n = 236) of on-demand therapy for mild GERD comparing pantoprazole 20 mg to esomeprazole 20 mg revealed heartburn symptoms to be less severe in the pantoprazole group.Citation42,Citation44

Special administration considerations of pantoprazole

Conventional pantoprazole is formulated as an enteric-coated, delayed-release tablet. However, pantoprazole is one of the few PPIs available in both iv and oral suspension form for the treatment of GERD in patients who are unable to tolerate the delayed-release capsule form.Citation11 Pantoprazole iv, which was approved in 2001 by the FDA, has equivalent efficacy to oral pantoprazole in its ability to suppress gastric acid output.Citation45 In 2007, the FDA also approved pantoprazole to be available in oral suspension form for the treatment of erosive esophagitis in patients unable to swallow capsules. Although studies are limited, a recent multicenter randomized control study (N = 60) showed oral suspension pantoprazole to provide similar efficacy to oral capsules in suppressing gastric acid output.Citation46

Safety and tolerability of pantoprazole

Short- and long-term clinical trials show oral pantoprazole 40 to 120 mg/day to have an excellent safety profile.Citation47 Studies ranging from 8 weeks to 4 years have shown the incidence of adverse effects to be as low as 1% to 3%.Citation47,Citation48 The most commonly reported side effects include diarrhea (2%), headaches (2%), nausea (1%), and constipation (1%). As with most PPIs, diarrhea is the most prevalent of these side effects.Citation11 Isolated case reports have associated pantoprazole use with thrombocytopenia and acute interstitial nephritis.Citation49Citation51 Recently, long-term PPI use has been shown to have increased class-associated incidence for hip fractures; however, no individual reports are available for pantoprazole.Citation52 Adverse side effects reported in patients with GERD who receive iv pantoprazole include headache, nausea, dizziness, flushing, and pain at the site of injection; however, data on tolerability in this subset of patients are limited.Citation53

Randomized, controlled, double-blind control trials in patients with GERD have shown that oral pantoprazole 40 mg/day has a comparable tolerability profile to oral omeprazole 20 mg/day and lansoprazole 30 mg/day after 8 weeks of therapy.Citation54,Citation55 In addition, oral pantoprazole 40 mg/day has similar tolerability comparing to H2RAs, such as ranitidine 300 mg/day and famotidine 40 mg/day.Citation56 Like other PPIs, pantoprazole can cause elevated gastrin levels; however, no data have been published indicating a correlation between elevated gastrin levels and an increased risk for cancer.Citation2,Citation10

There have been a few reported significant adverse drug interactions between pantoprazole and other medications metabolized through the CYP450 system. Unlike omeprazole, which recently has been shown to decrease the antiplate-let activity of clopidogrel, and which is also metabolized by CYP450, pantoprazole does not affect clopidogrel efficacy.Citation57 Given pantoprazole’s lower incidence for drug interactions compared to other PPIs, it is both safe and effective for long-term treatment of acid-related disorders in the elderly, a population at increased risk for adverse interactions due to medications. In addition, older patients have a higher incidence of developing severe esophagitis and its complications. Their relapse rate is also higher than that of younger patients if therapy with a PPI is not continued. Pantoprazole is also well tolerated in patients with renal failure and mild to moderate liver dysfunction (CHILDS class A/B). However, it has a relative contraindication in patients with severe liver disease.Citation11

Conclusion and future targets

The data reviewed here show that pantoprazole is both safe and effective in the initial treatment and maintenance therapy for the management of erosive and nonerosive GERD. It has superior efficacy to H2RAs and has relatively equivalent efficacy compared to other PPIs. It is efficacious for both esophageal healing and relief of symptoms associated with GERD. Pantoprazole’s favorable side effect profile and low incidence of drug–drug interactions make it ideal for using in special patient populations, such as the elderly and those with renal failure and moderate liver dysfunction. Future targets for study include more extensive trials on the use of continuous iv pantoprazole in the treatment of severe erosive esophagitis and long-term studies on the safety and efficacy of oral suspension formulation.Citation58 In addition, expanding FDA approval for the use of pantoprazole in children and adolescents is currently being considered.Citation59,Citation60

Disclosures

The authors declare no conflicts of interest.

References

  • VakilNvan ZantenSVKahrilasPDentJJonesRThe Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensusAm J Gastroenterol200610119001920 quiz194316928254
  • ScholtenTLong-term management of gastroesophageal reflux disease with pantoprazoleTher Clin Risk Manag2007323124318360632
  • HollenzMStolteMLabenzJPrevalence of gastro-oesophageal reflux disease in general practiceDtsch Med Wochenschr20021271007101211997867
  • RevickiDAWoodMMatonPNSorensenSThe impact of gastroesophageal reflux disease on health-related quality of lifeAm J Med19981042522589552088
  • EnckPDuboisDMarquisPQuality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)Scand J Gastroenterol Suppl1999231485410565623
  • DimenasEGliseHHallerbackBHernqvistHSvedlundJWiklundIQuality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?Scand J Gastroenterol1993286816878210982
  • DeVaultKRCastellDOUpdated guidelines for the diagnosis and treatment of gastroesophageal reflux diseaseAm J Gastroenterol200510019020015654800
  • FischerJGanellinCRAnalogue Based-Drug Discovery1st EditionWiley-VCH Verlag GmBh&Co.2006115136
  • PoolePPantoprazoleAm J Health Syst Pharm200158999100811402494
  • CheerSMPrakashAFauldsDLambHMPantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disordersDrugs20036310113312487624
  • DevaultKRPantoprazole: a proton pump inhibitor with oral and intravenous formulationsExpert Rev Gastroenterol Hepatol2007119720519072410
  • ShiSKlotzUProton pump inhibitors: an update of their clinical use and pharmacokineticsEur J Clin Pharmacol20086493595118679668
  • SachsGProton pump inhibitors and acid-related diseasesPharmacotheraphy1997172237
  • RichterJEFragaPMackMSabesinSMBochenekWPrevention of erosive oesophagitis relapse with pantoprazoleAliment Pharmacol Ther20042056757515339328
  • CalabreseCFabbriADiFeboGLong-term management of GERD in the elderly with pantoprazoleClin Interv Aging20072859218044079
  • AvnerDLClinical experience with pantoprazole in gastroesophageal reflux diseaseClin Ther20002211691185 discussion1149115011110229
  • ShinJMSachsGRestoration of acid secretion following treatment with proton pump inhibitorsGastroenterology20021231588159712404233
  • HartmannMTheissUHuberRTwenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazoleAliment Pharmacol Ther1996103593668791964
  • Van RensburgCJHoniballPJVan ZylJHSafety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis – a 2-year follow-upAliment Pharmacol Ther1999131023102810468676
  • TanakaMOhkuboTOtaniKStereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoinClin Pharmacol Ther20016910811311240974
  • KahrilasPJShaheenNJVaeziMFAmerican Gastroenterological Association Medical Position Satement on the management of gastroesophageal refluz diseaseGastroenterology20081351383139118789939
  • GalloSDibildoxMMoguelAClinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. Mexican Pantoprazole Study GroupRev Gastroenterol Mex199863111610068743
  • DammannHVon KleistEfficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastro-oesopghageal reflux disease: multicentre, open, randomised, control studiesInternational Clinical Practice Series1997152329
  • KovacsTOWilcoxCMDeVaultKMiskaDBochenekWComparison of the efficacy of panctoprazole vs nizatidine in the treatment of erosive oesophagtitis: a randomized active-controlled, double0blind studyAliment Pharmacol Ther2002162043205212452936
  • RichterJEBochenekWOral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study GroupAm J Gastroenterology20009530713080
  • MeneghelliUGBoaventuraSMoraes-FilhoJPEfficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rateDis Esophagus200215505612060043
  • ArmstrongDParePPericakDPyzykMSymptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux diseaseAm J Gastroenterol2001962849285711695354
  • MetzDCBochenekWJPantoprazole maintenance therapy prevents relapse of erosive oesophagitisAliment Pharmacol Ther20031715516412492745
  • SimonBMullerPPascuOGatzGSanderPHuberRMascherHIntra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux diseaseEur J Gastroenterol Hepatol20031579179912811310
  • MulderCJWesterveldBDSmitJMA double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trialEur J Gastroenterol Hepatol20021464965612072599
  • GlatzelDAbdel-QaderMGatzGPfaffenbergerBPantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapseDigestion20067414515417230024
  • KoernerTComparable efficacy of pantoprazole 40 mg vs omeprazole MUPS 40 mg in patients with GERD II/IIIGut200251A166
  • GohKLBenamouzigRSanderPSchwanTEfficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial–the EMANCIPATE studyEur J Gastroenterol Hepatol20071920521117301646
  • LaurtisenComparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERDGut200047Suppl III39 (A60).
  • HoltmannGInternational validation of a health-related quality of life questionnaire in patients with erosive gastro-oesophageal reflux diseaseAliment Pharmacol Ther20092961562519183145
  • ScholtenTPantoprazole 40 mg relieves primary reflux symptoms more rapidly than omeprazole MUPS 20 mg in patients with severe GERD symptomatologyGastroenterology2000118A1303
  • EhrlichALueckerPWWiedemannASanderPHuberRMascherHComparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administrationMethods Find Exp Clin Pharmacol199921475110222447
  • ThomsonAImpact of PPIs on patient focused symptomatology in GERDTher Clin Risk Manag200841185120019337426
  • OrrWCNight-time gastro-oesophageal reflux disease: prevalence, hazards, and managementEur J Gastroenterol Hepatol20051711312015647651
  • ParePArmstrongDPericakDPyzykMPantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidineJ Clin Gastroenterol20033713213812869883
  • BardhanKDStanghelliniVArmstrongDBerghoferPGatzGMonnikesHInternational validation of ReQuest in patients with endoscopy-negative gastro-oesophageal reflux diseaseDigestion200775Suppl 1485417489032
  • ScholtenTTeutschIBohuschkeMGatzGPantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux diseaseClin Drug Investig200727287296
  • KaspariSKupcinskasLHeinzeHBerghoferPPantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux diseaseEur J Gastroenterol Hepatol20051793594116093871
  • ScholtenTDekkersCPSchutzeKKornerTBohuschkeMGatzGOn-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trialDigestion200572768516113546
  • MetzDCPrathaVMartinPOral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux diseaseAm J Gastroenterol20009562663310710049
  • HoganDPrathaVRiffDOral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitisAliment Pharmacol Ther20072624925617593070
  • FittonAWisemanLPantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disordersDrugs1996514604828882382
  • Martin de ArgilaCSafety of potent gastric acid inhibitionDrugs200565Suppl 19710416335863
  • MooreISayerJANayarAAhmedSTapsonJSPantoprazole-induced acute interstitial nephritisJ Nephrol20041758058115372423
  • RaATobeSWAcute interstitial nephritis due to pantoprazoleAnn Pharmacother200438414514742791
  • WatsonTDStarkJEVestaKSPantoprazole-induced thrombocytopeniaAnn Pharmacother20064075876116569810
  • TargownikLELixLMMetgeCJPriorHJLeungSLeslieWDUse of proton pump inhibitors and risk of osteoporosis-related fracturesCMAJ200817931932618695179
  • PrathaVHoganDLLynnRBFieldBMetzDCIntravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trialDig Dis Sci2006511595160116927137
  • DupasJLHouckePSamoyeauRPantoprazole versus lansoprazole in French patients with reflux esophagitisGastroenterol Clin Biol20012524525011395670
  • CorinaldesiRValentiniMBelaicheJColinRGeldofHMaierCPantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre studyAliment Pharmacol Ther199596676718824655
  • ScholtenTHahnEGBosseckertHClinical tolerability of pantoprazole compared with ranitidine and famotidineInternational Clinicial Practice Series1997153136
  • Siller-MatulaJMSpielAOLangIMKreinerGChristGJilmaBEffects of pantoprazole and esomeprazole on platelet inhibition by clopidogrelAm Heart J2009157148e1e519081411
  • CaiQBarrieMOlejemeHRoserbergMA Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive EsophagitisDig Dis Sci2008531500150517985242
  • TsouVMBakerRBookLMulticenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD)Clin Pediatr (Phila)20064574174916968960
  • ToliaVBishopPRTsouVMGremseDSofferEFComerGMMulticenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr20064238439116641576